Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Lenvatinib in Advanced Biliary Tract Cancers
NCT04211168Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, lenvatinib in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
toripalimablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04211168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211168.